The company was founded in 2013 by Katherine A. High, Jeffrey Marrazzo, and Steven Altschuler in an effort to commercially develop treatments against haemophilia that High was working on at Children's Hospital of Philadelphia. In January 2015, the company became a public company, trading under the ticker $ONCE via a $161 million initial public offering led by Chief Legal Officer Joseph La Barge. Web23. feb 2024 · Spark Therapeutics Inc., the commercial anchor of Philadelphia’s burgeoning gene and cell therapy industry, is getting a new CEO, the company announced Wednesday. A Spark cofounder and its first CEO, Jeffrey D. Marrazzo, will step aside April 1 for Ron Philip, Spark’s chief operating officer.
Spark breaks ground on $575m gene therapy innovation center in Philadelphia
Web5. feb 2024 · At Spark Therapeutics, we start the the process with tactical reviews where demand and supply scenarios are focused across a near term window of several months and gradually build up to a multi-year master demand and supply planning window. WebSparfloxacin is reported as an ingredient of Spark in the following countries: Bangladesh. Important Notice: The Drugs.com international database is in BETA release. This means it … the cycle error code 12
Asklepios BioPharmaceutical, Inc. (AskBio) LinkedIn
WebAddress: 3737 Market St Ste 1300 Philadelphia, PA, 19104-5543 United States See other locations Phone: ? Website: www.sparktx.com WebIndication. LUXTURNA (voretigene neparvovec-rzyl) is a prescription gene therapy product used for the treatment of patients with inherited retinal disease due to mutations in both copies of the RPE65 gene, which can only be confirmed through genetic testing. You must also have enough remaining cells in your retina (the thin layer of tissue in ... Web23. feb 2024 · Spark Therapeutics Inc., the commercial anchor of Philadelphia’s burgeoning gene and cell therapy industry, is getting a new CEO, the company announced Wednesday. … the cycle exception_access_violation